Novel polypeptides and nucleic acids encoding bolekine
AssigneeGenentech, Inc.
InventorsSherman Fong, Audrey Goddard, Kenneth J. Hillan, Iris Roth, William I. Wood
Life of this patent
Estimating the term…
Abstract
The present invention is directed to Bolekine polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims46
An isolated nucleic acid molecule which comprises (a) a DNA molecule encoding a Bolekine polypeptide comprising the sequence of amino acid residues from about 1 or about 34 to about 111 of FIG. 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of Bolekine (a).
An isolated nucleic acid molecule comprising DNA which comprises (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on Oct. 31, 1997 under ATCC Deposit No. 209424 (DNA39523-1192), or (b) the complement of the DNA molecule of (a).
A nucleic acid molecule deposited with the ATCC under accession number 209424 (DNA39523-1192).
An isolated nucleic acid molecule encoding a Bolekine polypeptide comprising DNA that hybridizes to the complement of the nucleic acid sequence that encodes amino acids 1 or about 34 to about 111 of FIG. 2 (SEQ ID NO:2).
The isolated Bolekine polypeptide comprising amino acid residues 1 or about 34 to about 111 of FIG. 2 (SEQ ID NO:2).
The isolated Bolekine polypeptide which is encoded by the cDNA insert of the vector deposited with the ATCC on Oct. 31, 1997 as ATCC Deposit No. 209424 (DNA39523-1192).
An isolated Bolekine polypeptide comprising the sequence of amino acid residues from 1 or about 34 to about 111 of FIG. 2 (SEQ ID NO:2), or a fragment thereof sufficient to provide a binding site for an anti-Bolekine antibody.
An isolated polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a Bolekine polypeptide comprising the sequence of amino acid residues from 1 or about 34 to about 111 of FIG. 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a), (ii) culturing a host cell comprising said test DNA molecule under conditions suitable for the expression of said polypeptide, and (iii) recovering said polypeptide from the cell culture.
A chimeric molecule comprising a Bolekine polypeptide fused to a heterologous amino acid sequence.
An antibody which specifically binds to a Bolekine polypeptide.
An agonist to a Bolekine polypeptide.
An antagonist to a Bolekine polypeptide.
A composition of matter comprising (a) a Bolekine polypeptide, (b) an agonist to a Bolekine polypeptide, (c) an antagonist to a Bolekine polypeptide, or (d) an anti-Bolekine antibody, in admixture with a pharmaceutically acceptable carrier.
A method for determining the presence of a Bolekine polypeptide in a sample suspected of containing said polypeptide, said method comprising exposing said sample to an anti-Bolekine antibody and determining binding of said antibody to a component of said sample.
A method of diagnosing an immune related disease in a mammal, said method comprising detecting the level of expression of a gene encoding Bolekine polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of an immune related disease in the mammal from which the test tissue cells were obtained.
A method of diagnosing an immune related disease in a mammal, said method comprising (a) contacting an an anti-Bolekine antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of an immune related disease in the mammal from which the test tissue cells were obtained.
A method of identifying a compound that inhibits the activity of a Bolekine polypeptide, said method comprising contacting cells which normally respond to said polypeptide with (a) said polypeptide and (b) a candidate compound, and determining the lack responsiveness by said cell to (a).
A method of identifying a compound that inhibits the expression of a gene encoding a Bolekine polypeptide, said method comprising contacting cells which normally express said polypeptide with a candidate compound, and determining the lack of expression said gene.
A method of identifying a compound that mimics the activity of a Bolekine polypeptide, said method comprising contacting cells which normally respond to said polypeptide with a candidate compound, and determining the responsiveness by said cell to said candidate compound.
A method of stimulating the proliferation of T-lymphocytes, said method comprising contacting T-lymphocytes with an effective amount of (a) a Bolekine polypeptide or (b) an agonist of (a), wherein the proliferation of said T-lymphocytes is stimulated.
A method of inhibiting the proliferation of T-lymphocytes, said method comprising contacting T-lymphocytes with an effective amount of an antagonist of a Bolekine polypeptide, wherein the proliferation of said T-lymphocytes is inhibited.
A method of enhancing the infiltration of inflammatory cells into a tissue of a mammal, said method comprising administering to said tissue an effective amount of (a) Bolekine polypeptide or (b) an agonist of (a), wherein said infiltration is enhanced.
A method of inducing the differentiation of puripotent cells into neuronal cells in a mammal, said method comprising administering an effective amount of (a) a Bolekine polypeptide or (b) an antagonist of Bolekine polypeptide, wherein said cells differentiate to a state wherein neuronal markers can be detected.
Dependencies are inferred from the claim text.